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1. Introduction 
Neuropeptide Y (NPY) is a 36 amino acid peptide, widely distributed in the nervous system 
where it plays the role of a neurotransmitter and neuromodulator (Chronwall et al., 1985; 
Gray & Morley, 1986). It belongs to the pancreatic polypeptide family (PP family) together 
with peptide YY (PYY) and pancreatic polypeptide (PP), which are mainly gut and 
endocrine regulatory peptides (Tatemoto et al., 1982). All these peptides have a common 
hairpin-like tertiary structure, consisting of an N-terminal poly-proline helix and a long 
alpha-helix connected by a beta turn (Allen et al., 1987; Glower et al., 1984). NPY contains 5 
tyrosine residues in its primary structure, (Fig.1) therefore, it is named neuropeptide Y or 
neuropeptide tyrosine, as “Y” is an abbreviation of tyrosine.  
Tyr1-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu10-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr20- 
Tyr-Ser-Ala-Leu-Arg-His-Tyr-IIe-Asn-Leu30-IIe-Thr-Arg-Gln-Arg-Tyr36-NH2 
Fig. 1. Primary structure of NPY (human, rat). 
NPY is present in the central and peripheral neurons and is described as one of the most 
abundant peptides in the brain (Chronwall, 1989). In the brainstem, it often coexists with 
noradrenaline (NA) and adrenaline (A) in some projecting catecholaminergic neurons, and 
with serotonin in human and rabbit, (but not rat) medullary neurons (Everitt & Hökfelt, 
1989). In the forebrain NPY is present mainly in local inhibitory interneurons, where it 
coexists with GABA and often with somatostatin (Everitt & Hökfelt, 1989). Besides the 
central nervous system (CNS), NPY occurs also in the periphery: in chromaffin cells of the 
adrenal medulla (coexisting with A and NA), in sympathetic neurons (coexisting with NA) 
and in some (few) parasympathetic neurons. NPY was also found in blood cells, spleen, 
bone marrow, magakaryocytes and thrombocytes (Ericsson et al., 1987; Persson et al., 1989). 
NPY is involved in many physiological functions, such as: regulation of blood pressure (in 
the periphery NPY is a potent vasoconstrictor), cardiorespiratory parameters and body 
temperature, control of the release of luteinizing hormone releasing hormone (LHRH)  
and corticotropin releasing factor (CRF), and modulation of feeding, sexual behavior, pain,  
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Fig. 2. Microphotographs showing NPY–immunoreactive neurons in the frontal sections of 
the mouse brain. A: the cerebral cortex; B: the hilar region of the hippocampus. Nerve cell 
bodies and varicose fibres can be seen. ABC staining. 
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anxiety (NPY has a strong antianxiety effect), circadian rhythms, memory processing, 
inhibition of the release of other neurotransmitters (Colmers et al., 1990; Danger et al., 1990; 
Gray & Morley, 1986; Greber et al., 1994; Wettstein, et al., 1995). NPY plays an important 
role in the regulation of neuronal activity, it reduces epileptiform activity in the 
hippocampus (Woldbye et al., 1997) by inhibition of glutamate release (Colmers & 
Bleakman, 1994; Greber et al., 1994; Silva et al., 2005b; Vezzani et al., 1999).  
The numerous and diverse actions of NPY are mediated by specific, G-protein coupled 
heptahelical receptors, called Y receptors. Six Y receptors have been identified (Y1, Y2, Y3, 
Y4, Y5, and y6) based on different pharmacological profiles (Dumont et al., 1992). Five of 
them, except for Y3, have been cloned. The Y1, Y2 and Y5 receptors preferentially bind NPY 
and PYY, whereas Y4 is activated preferentially by PP. The Y3 receptor has not been cloned 
till now and was only pharmacologically characterized as having a very low affinity for PYY 
(ten times weaker than for NPY). In the brain, it was found only in the nucleus of the 
solitary tract. The y6 receptor functions only in the mouse and the rabbit and is absent in the 
rat, human and other primates (Michel et al., 1998; Silva et al., 2002, 2005a). Activation of all 
Y receptor types inhibits adenylate cyclase and in most of cells, that effect is abolished by 
botulin toxin, which indicates that Gi/Go proteins participate in the signal transduction 
from Y receptors to adenylate cyclase. The Y receptor activation influences also ion channels 
but the final effects depend on the type of target cell. It was best characterized for Y1 and Y2 
receptors. In neurons, Y1 receptor activation enhanced Ca++ availability via inositol 
triphosphate (IP3)-mediated mobilization of intracellular Ca++ stores or by enhancing 
calcium ion entry through L-type channels, causing neuronal excitation. Inhibition of K+ 
channels after Y1 stimulation has also been described. On the other hand, Y2 receptor 
activation reduced Ca++ availability (via N-type channels) and inhibited neuronal function. 
Much evidence supports the excitatory role of Y1 receptors but opposite effects have also 
been noted, e.g. small neurons of dorsal root ganglia are inhibited by Y1 receptor activation 
by their hyperpolarization. The Y5 receptors have inhibitory properties and such effects 
have also been postulated for other Y receptors but were much less studied.  
NPY activates all Y receptors with similar potency as PYY except for Y3 which is 
characterized by a higher affinity for NPY than for PYY and Y4 receptor which binds PP 
with high affinity, but PYY and NPY with very low affinity. If we want to study a role of 
particular Y receptor types, a more specific ligands are needed. Agonistic ligands are still 
only peptides (no smaller non-peptide molecules have been introduced). Y1 receptors are 
selectively activated by peptides NPY or PYY modified at the C-terminal end i.e. [Pro34]-
NPY, [Leu31,Pro34]-NPY, [Leu31,Pro34]-PYY. Such modification induces a loss of Y2 receptor 
affinity. It indicates that N-terminal part of the peptide is essential for Y1 receptor binding. 
In contrast, the binding to Y2 receptors does not require N-terminal sequence but C-terminal 
part of the peptide is crucial. Thus, the selective agonists of Y2 receptors include NPY (13-
36) and some cyclic analogs of NPY. Receptors of Y5 type are activated by NPY(2-36), 
PYY(3-36), but the peptides stimulate also Y2 receptors. Selective Y5 receptor agonists were 
synthesized during the last 10 years, and one of them, a chimeric peptide of PP with 
changed NPY fragment, [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic Polypeptide was 
described as a very selective Y5 agonist (Cabrele et al., 2000). A better situation is with the 
availability of non-peptide antagonists of Y receptors. There are several non-peptide Y1 
receptor antagonists and one of them BIBO3304 has a good selectivity profile and high 
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affinity (Brothers & Wahlestedt, 2010; Dumont et al., 2000). Y2 receptors are successfully and 
specifically blocked by BIIE0246 (Doods et al., 1999) but submicromollar affinities for opioid 
and alpha1 adrenergic receptors were also noted. Y5 receptors can be antagonized by the 
compounds called MK-0557, S-2367, L152,804 or 2-36[K4,RYYSA(19-23)]PP, and a very 
selective compound, CGP 71683 synthesized in the last years showed more than 1000-fold 
higher selectivity for Y5 over Y1, Y2 and Y4 receptors (Brothers & Wahlestedt, 2010). 
Receptor Agonists Antagonists 
Y1R NPY = PYY = Leu31,Pro34NPY >> NPY13-36 > PP BIBP3226 
  BIBO3304 
  BMS193885 
   
Y2R NPY = PYY ≥ NPY13-36 >> Leu31,Pro34NPY > PP BIIE0246 
 PYY3-36 SF 11 
  JNJ 5207787 
  JNJ 31020028 
   
Y5R NPY ≥ PYY ≥ PP CGP 71683 
 [cPP1-7,NPY19-23,Ala31Aib32, Gln34]-hPP MK-0557 
 BWX 46 S-2367 
  L-152,804 
NPY – neuropeptide Y, PYY – peptide YY, PP- pancreatic polypeptide 
Table 1. Representative NPY receptor ligands for Y1, Y2 and Y5 receptors 
2. Modulation of an excitatory glutamatergic transmission by NPY 
Glutamate is the most abundant excitatory neurotransmitter in the mammalian brain and 
participates in the changes of synaptic transmission underlying learning and memory (Bliss 
& Collingridge, 1993), but on the other hand, an overactivation of glutamatergic 
transmission may lead to excitotoxic cell death (Ankarcrona et al., 1995; Choi, 1985; Conn & 
Pin, 1997). It is generally assumed that excitotoxicity is a common pathological condition to 
a variety of neuronal degenerations. It comprises supraphysiological stimulation of 
ionotropic glutamate receptors and an increase in intracellular Ca++ which triggers 
downstream processes resulting in neuronal death (acc. to Silva et. al., 2005a). Thus, control 
of extracellular glutamate concentration seems to be critical for both neuronal signaling and 
survival. One of the important functions of NPY is related to the inhibition of glutamate 
release and reduction of glutamatergic excitatory activity which may result in 
neuroprotection. It was found that NPY reduced epileptiform activity in the hippocampus 
and cortex (Bijak, 1999; Bijak & Śmiałowska, 1995; Klapstein & Colmers, 1997), inhibited 
glutamate release (Colmers, 1990; Greber et al., 1994; Silva et al., 2001) and reduced kainic 
acid (KA)-induced seizures (Madsen et al., 1999; Woldbye et al., 1997). Moreover, increases 
in the synthesis and content of NPY in the limbic structures were found after seizures of 
different origin (Bellmann et al., 1991; Bendotti et al., 1991; Marksteiner et al., 1990; 
Schwarzer et al., 1996; Silva et al., 2005a; Śmiałowska et al., 2003) which may indicate a 
possibility of neuroprotective role of endogenous NPY. 
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Our earlier studies showed the neuroprotective effects of NPY against KA-induced 
neurotoxicity both in vivo in the rat hippocampus (Śmialowska et al., 2003) and in vitro in the 
hippocampal and cortical neuronal cultures (Domin et al., 2006). Results of other authors 
were controversial showing both protective and toxic effects of NPY (Chen & Cheung, 2002; 
Cheung & Cechetto, 2000). The cause of such a discrepancy may be connected with 
differentiation of Y receptors.  
2.1 The role of particular Y receptors in neuroprotection 
Among NPY receptors, Y1R, Y2R and Y5R were postulated to play the most important role 
in the regulation of neurotoxicity and neuroprotection. Since specific agonists and 
antagonists of those receptors have been synthesized (Aguirre et al., 1990; Cabrele et al., 
2000; Doods et al., 1999; Dumont et al., 2000; Fuhlendorff et al., 1990; Rudolf et al., 1994; 
Wieland et al., 1998) the studies on the role of particular receptors in neuroprotection 
became possible. Most of evidences demonstrated neuroprotective effects after Y2 and Y5 
receptor agonists (Silva et al., 2003b, 2005a; Śmialowska et al., 2009; Wu & Li, 2005). 
Neuroprotective role of Y2 and Y5 receptor stimulation was also suggested by 
electrophysiological and behavioral studies in which the activation of these receptors 
suppressed epileptiform bursting or seizures (Bijak, 1999; Klapstein & Colmers, 1997; Marsh 
et al., 1999; Woldbye et al., 1997; Vezzani et al., 1999). The role of Y1R in neuroprotection is 
ambiguous. The activation of Y1 receptors produced neuroprotective effects in kainate 
excitotoxicity model of rat organotypic hippocampal slice cultures (Xapelli et al., 2007) and 
in methamphetamine neurotoxicity model in the mouse striatum (Thieriet et al., 2005), but 
in both models Y1R had a little weaker effect than Y2R agonists. Excitotoxicity induced by 
AMPA in organotypic mouse hippocampal slice cultures showed that AMPA-induced 
degenerations of CA1 and CA3 pyramidal neurons were strongly inhibited by Y2 but not Y1 
or Y5 receptor agonists (Xapelli et al., 2008). More detailed studies in hippocampal slices 
have shown that neuroprotective properties of a particular Y receptor may depend on the 
region where the receptor is located. Thus Y1, Y2 and Y5 receptor agonists were 
neuroprotective against AMPA or kainate excitotoxicity in dentate granule cells and CA3 
region, while CA1 pyramidal neurons were protected only by Y2 agonist (Silva et al., 2003a, 
2005a). On the contrary, the excitotoxic effects of Y1 receptor activation in the rat 
hippocampus were suggested by the results of Gariboldi et al. (1998) in which Y1R 
stimulation potentiated convulsions, while administration of Y1R antagonist inhibited 
kainate-induced seizures. Moreover, studies in an ischemic model both in vitro and in vivo, 
have demonstrated that Y1 receptor activation enhances neurodegeneration, while Y1R 
antagonists produced neuroprotective effects (Chen & Cheung, 2003, 2004). No protection 
after a Y1 receptor agonist was also found in our studies both in vitro and in vivo 
(Śmialowska et al., 2009). 
2.1.1 Neuroprotective effect of Y receptor agonists in kainic acid-induced 
excitotoxicity 
The model of kainic acid (KA)-induced excitotoxicity was described as a good and validated 
simulation of different excitotoxic neurodegenerations, connected with the secondary 
release of endogenous glutamate (Coyle, 1983; Ferkany & Coyle, 1983; Malva et al., 1998; 
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Wang et al., 2005). The KA activates kainate receptors, which belong to ionotropic glutamate 
receptors, but effects after KA develop progressively and endogenous glutamate release 
enhances degeneration. Therefore, the KA-model seems to be especially suitable for 
studying the delayed neuroprotection.  
The main goal of our studies was to explore a possibility of neuroprotection induced by 
NPY or specific Y receptor ligands. We focused our attention on Y1, Y2 and Y5 receptors, as 
it is generally assumed that these receptors play the most important role in the regulation of 
neurodegeneration and neuroprotection. Moreover, we investigated the efficacy of the 
treatment delayed even by a few hours while in the majority of other studies NPY and its 
ligands were applied before or simultaneously with a neurotoxic damage, however, the 
delayed treatment resembles more closely the situation of patients, who are usually treated 
some time after an injury. 
We performed studies both in vitro and in vivo (Śmialowska et al., 2009). In in vitro 
experiments primary cultures of mouse cortical and hippocampal neurons were used. The 
cultures were exposed to KA for 24 or 48 h and then Y receptor ligands were added 30 min, 
1, 3 or 6 h after starting the KA exposure. Cell death was quantified by measurements of 
lactate dehydrogenase (LDH) release from damaged cells into the cell culture media. 
Apoptosis was evaluated by measurements of caspase-3 activation and additionally by 
fluorescent Hoechst 33342 staining which visualized condensed DNA fragments, 
characteristic for apoptotic cells. A huge increase in the LDH release and caspase-3 
activation was found after the KA and these increases were strongly attenuated by both  
Y2 receptor agonist (NPY13-36) and Y5 receptor agonist ([cPP1-7,NPY19-
23,Ala31,Aib32Gln34]hPP), added as late as 3 hours after starting KA intoxication. The results 
indicated neuroprotective and antiapoptotic effects of these peptides. Receptor specificity 
was confirmed by experiments with antagonists which prevented the neuroprotection. No 
neuroprotective effects were observed after Y1 receptor agonist [Leu31, Pro34]-NPY given 
after the KA (for details see Śmialowska et al., 2009). Our in vitro results are in line with the 
studies of other authors showing the protective effect of Y2 and Y5 receptors, but not Y1 in 
the KA-induced excitotoxicity (Silva et al., 2001, 2003b; Woldbye & Kokaia, 2004; Xapelli et 
al., 2007). 
The same picture of Y receptor efficacy in neuroprotection emerges also from the in vivo 
experiments. Wu and Li (2005) found that NPY and specific Y2 and Y5 receptor agonists 
rescued mouse hippocampal pyramidal neurons from KA-induced apoptosis (visualized by 
the TUNEL staining) when the peptides were intracerebroventricularly (icv) injected as late 
as 2 or 8 h after intraperitoneal KA injection. Also in our in vivo studies the neuroprotective 
effects were found after treatment of the peptides delayed by 30 min or 1 h, but not 3 h, after 
the KA injection. Our model was different than that of the above-mentioned authors as we 
used rats and injected KA into the CA1 hippocampal region in a dose and manner which 
did not induce seizures. The peptides were also microinjected intrahippocampally. Brains 
were removed and fixed 7 days after the treatment and degeneration and protection were 
evaluated by stereological counting of neurons in the CA pyramidal layer in the dorsal 
hippocampus. The results showed the protective effects of Y2 and Y5, but not Y1 receptor 
agonists (for details see Śmialowska et al., 2009). 
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Fig. 3. Microphotographs of frontal sections of the rat brain hippocampi, stained with cresyl 
violet for visualization of nerve cell bodies. A: The hippocampus after KA injection into the 
CA1 region. Strong degeneration of pyramidal neurons and extensive gliosis are seen. B: 
non-degenerated, contralateral hippocampus microinjected with a phosphate buffer used as 
a control side. C: Neuroprotective effect of Y2 receptor agonist injected 30 min after the KA. 
The lesion is much smaller. D: A similar neuroprotective effect is seen after Y5 receptor 
agonist microinjected 30 min after the KA. After Y2 (C) and Y5 (D) receptor agonists 
pyramidal neurons are much more numerous than after KA alone (A). 
2.1.2 The role of NPY and Y receptors in ischemic neurodegeneration 
Much less is known about the neuroprotective role of NPY in ischemic degenerations. A 
possibility of such function of endogenous NPY was postulated on the basis of the 
observations that NPY-immunoreactivity increased locally in the cerebral cortex around the 
site of infarct following middle cerebral artery occlusion (MCAO) in rats (Allen et al., 1995, 
Cheung & Cechetto, 1997; Cheung et al., 1995). On the other hand, an increase in the infarct 
volume in a similar MCAO model was observed after intravenous or central NPY 
administration into the rat (Chen & Cheung, 2002). The effect was suggested to be connected 
with a vasoconstrictive action of NPY, via Y1 receptors, as these authors reported a 
reduction of the cerebral blood flow after NPY injection. The possibility of neuroprotective 
function of endogenous NPY was also suggested by the experiments in which ischemic 
preconditioning induced an increase in NPY-immunoreactivity in the gerbils’ hippocampus 
(Duszczyk et al., 2009). Quite different results were obtained when antisense oligonucleotide 
to Y1 receptors was given to rats prior to MCAO. Such treatment strongly reduced cortical 
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Y1 receptor density and evoked a huge increase in the infarct volume (Cheung & Cechetto, 
2000). The result suggested a positive role of Y1 receptors in the protection against ischemia 
as the lack of Y1 receptors resulted in an increased degeneration. However, other studies 
have demonstrated that Y1 receptor activation enhanced ischemic degenerations. Again in 
MCAO model in rats intracerebroventricular injection of Y1 agonist increased, while 
antagonist reduced the infarct volume (Chen & Cheung, 2003). Similarly in in vitro model in 
which neuronal cultures were deprived of oxygen and glucose (OGD model) Y1 receptor 
agonist worsened while antagonist improved survival of neurons (Chen & Cheung, 2004). 
Therefore, the results of studies on the role of NPY and Y receptors in ischemic 
neurodegenerations obtained so far were divergent and insufficient. Our group also 
examined this problem. We found that Y2 receptor agonist (NPY13-36) given 
intracerebroventricularly 30 min after the onset of ischemia significantly diminished the 
infarct volume in the rat transient MCAO model (Śmialowska et al., 2009). Our preliminary 
in vitro studies on primary cultures of mouse cortical neurons indicated also that in cultures 
subjected to oxygen and glucose deprivation (OGD model) Y2 receptor agonist induced 
neuroprotection and moreover, similar protective effect was observed after Y5 receptor 
agonist but not after Y1 receptor agonist (data in preparation).  
2.1.3 The role of NPY and Y receptors in chronic neurodegenerative diseases 
An involvement of NPY in chronic neurodegenerations has been postulated on the basis of 
clinical studies and animal or in vitro experiments.  
Huntington’s disease 
Patients with Huntington’s disease (HD) have pathological changes mainly in the striatum 
and cerebral cortex and show characteristic abnormal motor activity (chorea movements), 
cognitive impairment and emotional disturbances (Colton & Vitek, 2006). HD is one of 
neurodegenerative diseases in which a pathological protein is expressed in the cells. The 
hallmark of HD is the protein huntingtin with pathological repeat length and the most 
affected neurons are medium spiny neurons in the striatum. Loss of these neurons, 
projecting to the globus pallidus and substantia nigra is the main reason of the motor 
abnormalities in HD. In contrast, NPY interneurons in the striatum are relatively resistant to 
degenerations in HD. Many cortical and striatal interneurons contain NPY, usually 
coexisting with somatostatin (SOM), and it was found that the level of both NPY and SOM 
increased 3-5 fold in the caudate, putamen, nucleus accumbens and cortex in HD in 
comparison to control brains (Beal et al., 1988; Dawbarn et al., 1985; Mazurek et al., 1997). 
The analysis of transgenic mouse models of HD displayed divergent results, both decreases 
or increases in NPY and SOM and their mRNAs were reported (Figueredo-Cardenas et al., 
1994; Kumar, 2004; Luthi-Carter et al., 2000). The degeneration of the striatal medium spiny 
neurons in HD may be connected with their abundant glutamatergic innervation from the 
cortex and high density of glutamate receptors (Kumar et al., 1997; Sieradzan & Mann, 2001; 
Zeron et al., 2002), so excitotoxic cell death is supposed to occur in HD. Therefore, NPY 
could be neuroprotective but till now a possible role of NPY in HD is unclear. Experiments 
with transgenic mouse model of HD (R6/2 strain) showed that a single intraventricular 
injection of NPY improved motor function, increased survival time and diminished cerebral 
and striatal atrophy. The positive effects were proposed to be connected with an increased 
www.intechopen.com
 Neuroprotective Effects of Neuropeptide Y and Y2 and Y5 Receptor Agonists In Vitro and In Vivo 
 
45 
neurogenesis in the subventricular zone (Decressac et al., 2010) induced by NPY and 
migration of new cells into the striatum, where they differentiate to GABAergic 
interneurons. On the other hand, the development of the disease in HD patients proceeded 
in spite of NPY increase, therefore, it may be supposed that protective action of NPY, if 
happened, is insufficient for preventing the progression of the disease. 
Alzheimer’s disease 
Alzheimer’s disease (AD) is a chronic brain neurodegeneration with progressive memory 
loss, cognitive dysfunction, various neuro-psychiatric and behavioural disturbances that 
seriously interfere with daily life activity and eventually lead to death. The 
neuropathological hallmarks of AD are senile plaques (containing a pathological form of 
amyloid beta) and neurofibrillary tangles (containing hyperphosphorylated tau protein). 
Advanced stages of AD are characterized by an extensive neuronal loss especially in the 
hippocampus, cortex and nucleus basalis of Meynert. The damage in the hippocampal and 
cortical regions was postulated to be associated with dementia. NPY is present in some 
hippocampal and cortical interneurons and seems to have a role in learning and memory 
thus the possible involvement of this peptide in AD pathogenesis and/or symptoms has 
been studied but results are divergent. A number of clinical studies showed a reduced or 
unchanged level of NPY in the cerebrospinal fluid (Atack et al., 1988; Edvinsson et al., 1993; 
Heilig et al., 1995; Martignoni et al., 1992; Minthon et al., 1990; Nilsson et al., 2001) or plasma 
(Koide et al., 1995) of AD patients. Losses of cortical receptor sites for NPY (Nordberg, 1992) 
and decrease in NPY receptor density in the hippocampus and temporal cortex but not in 
the putamen have also been reported (Martel et al., 1990). Immunohistochemistry of brain 
sections evidenced a strong reduction in the number of NPY-immunoreactive neurons in the 
hippocampal formation and enthorinal cortex and alternation of the morphology of the 
remaining neurons (Kowall & Beal, 1988). The results obtained from studies of a transgenic 
mouse model of AD, overexpressing amyloid precursor protein and demonstrating amyloid 
plaques showed quite different changes in NPY, namely an increased NPY 
immunoreactivity in the hippocampus and enthorinal cortex (Diez et al., 2000, 2003). 
However, other models that co-express amyloid plaques and neurofibrillary tangles have 
altered NPY levels and more resemble changes in human AD (Oddo et al., 2003, 2004).  
A possibility of neuroprotective effects of NPY in AD neurodegeneration arises from the 
neuroprotective potential of NPY in excitotoxicity and its ability to decrease the calcium ion 
influx into neurons, that is one of the mechanism of this protection. Since amyloid beta 
(Abeta) peptides were found to disrupt calcium ion homeostasis and increased 
intraneuronal Ca++ (Fedrizzi & Carafoli, 2011; Pereira et al., 2005; Shirvany et al., 2007), 
NPY may inhibit this damaging process. Moreover, it was found that NPY increased the 
production of neurotrophins and protected SY5Y neuroblastoma cells against beta amyloid 
toxicity with concomitant increase in neurotrophin production (Croce et al., 2011). 
Additional mechanisms of therapeutic action of NPY in AD might be related to the 
activation of neurogenesis in the hippocampus (Howell et al., 2005, 2007) as well as to 
neurogenesis and cell proliferation in other structures (see above in the chapter about HD). 
A new possibility of neuroprotection based on NPY has also been postulated by Rose et al. 
(2009), who found protective effects of neuropeptide fragments (mainly NPY 21-36 and 31-
36) derived from neprilysin processing in a transgenic mouse model of AD. No studies of 
the role of specific Y receptors were performed yet.  
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Parkinson’s disease 
Parkinson’s disease (PD) is a chronic neurodegeneration characterized mainly by 
progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta 
with disappearance of their projections into the striatum. It leads to development of motor 
symptoms such as bradykinesia, rigidity and tremor. Therapies used in PD can temporarily 
alleviate motor symptoms but do not prevent progression of the disease as the mechanism 
of PD development is still unclear. There are only a few studies concerning NPY in human 
PD. A decrease in NPY level in the cerebrospinal fluid (Martignoni et al., 1992), no changes 
in the cortex and hippocampus (Allen et al., 1985) or decrease in adrenal medulla (Stoddard 
et al., 1991) were described in PD patients. Besides, it has been postulated that NPY may 
play some role in the pathogenesis and/or symptoms of PD as both nerve cell bodies and 
terminals containing NPY are quite abundant in extrapyramidal structures engaged in the 
disease and, moreover, a reciprocal interactions were found between dopaminergic and 
NPY neurons. In animal experiments, a decrease or disappearance of dopaminergic 
innervation in the striatum (such situation occurs in PD) induced a significant increase in 
NPY synthesis and content in the striatal interneurons (Engber et al., 1992; Kerkerian et al., 
1986, 1988; Midgley et al., 1994; Śmialowska, 1995). In situ hybridization 
immunohistochemical studies of postmortem human brain structures showed an increase in 
NPYmRNA in the striatum especially in the ventral caudate nucleus and the nucleus 
accumbens (Cannizzaro et al., 2003) in PD.  
A regulatory function of NPY in DA transmission was demonstrated in rats, as an NPY 
injection into the striatum increased the DA turnover in that structure (Beal et al., 1986). 
More detailed studies on the role of particular Y receptors in the rat striatum have shown 
that Y2 receptor activation enhanced dopamine synthesis while Y1 and Y5 receptor 
stimulation attenuated the DA synthesis (Adewale et al., 2005). Since no genetic mouse 
model of PD currently exists, studies have focused primarily on the models with lesioned 
nigro-striatal dopaminergic systems. The lesions were performed by means of dopaminergic 
toxins 6-hydroxydopamine or MPTP. Recently, Decressac et al., (2011a) described a 
neuroprotective effect of NPY in PD models. They found that NPY protected dopaminergic 
neuroblastoma cells (SH-SY5Y) from 6-hydroxydopamine induced toxicity. The 
neuroprotective effect of NPY was also confirmed in vivo, in the rat and mouse model of PD 
in which striatal NPY injection inhibited dopaminergic degenerations induced by the toxins 
and improved motor performance. Moreover, detailed studies using Y receptor ligands 
evidenced a protective action of Y2 but not Y1 receptors both on dopamine neurons and the 
behavioral impairments (Decressac et al., 2011a). Therefore, the authors suggested a 
possibility of therapeutic use of NPY ligands in the future. 
2.2 How does NPY modulate neurodegenation and neuroprotection? 
NPY appears to be particularly promising for neuroprotection, since it has a significant 
modulating effect on excitatory neurotransmission. As mentioned above, many studies have 
shown that NPY inhibits glutamatergic transmission (Bijak, 2000; Colmers et al., 1987; 
Greber et al., 1994; Klapstein & Colmers, 1992; McQuiston & Colmers 1996; Śmialowska et 
al., 1996;) through presynaptic inhibition of glutamate release from nerve terminals (Greber 
et al., 1994; Silva et al., 2003a). It is assumed that such inhibition is associated with the 
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inhibition of N-type calcium channels (Qian et al., 1997; Silva et al., 2001; Silva et al., 2003a). 
Since NPY receptors activate signaling pathways involved in the regulation of intracellular 
Ca2+ homeostasis (Silva et al., 2002), one of the possible mechanism of neuroprotective action 
of NPY consists in the inhibition of calcium channels thereby inhibiting the influx of calcium 
ions into the cell (Thiert et al., 2005; Xapelli et al., 2007). In our studies, NPY as well as Y2R 
and Y5R agonists inhibited the toxic effects of KA, decreased the KA-induced caspase-3 
activation and the number of apoptotic bodies (Śmialowska et al., 2009). It is known that KA 
disturbs the homeostasis of calcium ions in cells, cytochrome c release and caspase-3 
activation, which leads to cell death (Wang et al., 2005). Therefore, it has been proposed that 
the antiexcitatory and antiapoptotic properties of the peptides under study are connected 
with a decrease in the input of calcium ions into neurons and a decrease in glutamate 
release. 
As mentioned above, the role of Y1 receptors in neuroprotection is unclear. It is supposed 
that the neurotoxic effect of Y1R activation observed in our and other studies may be due to 
the fact that these receptors are situated mainly postsynaptically, and their activation 
induces calcium influx and inhibition of potassium channels, which increases neuronal 
excitability (Dumont et al., 1992; Gobbi et al., 1996). Stimulation of calcium release from the 
endoplasmic reticulum (Aakerlund et al., 1990) and enhancement of nitric oxide production 
(Bitran et al., 1999; Chen et al., 2002) have also been proposed as possible mechanisms of 
neurotoxicity after Y1R activation. On the other hand, it has been found in the brain that 
some Y1 receptors are located presynaptically (Kopp et al., 2002) and the putative 
neuroprotective mechanism of action Y1R agonist in some models might be due to the 
presynaptic inhibition of glutamate release by inhibition of Ca++ entry (McQuiston et al., 
1996; Silva et al., 2001; Silva et al., 2003a, 2003b). Such presynaptic inhibitory Y1 receptors 
were found, for instance, in the hippocampal dentate region (McQuiston et al., 1996; Silva et 
al., 2001, 2003b), rat cerebral cortex (Wang, 2005) or arcuate nucleus (Sun & Miller, 1999). 
The Y1 receptor stimulation may have also positive effects in neurodegenerations by quite 
different mechanism. It has been shown that NPY promotes neurogenesis and proliferation 
of progenitor cells in the rat dentate gyrus of the hippocampal formation and the effects are 
mediated by Y1 receptors as they were also observed after Y1R but not after Y2R agonists 
(Descressac et al., 2011b; Howell et al., 2005; Kopp et al., 2002; Xapelli et al., 2006). Moreover, 
the proliferation was reduced in Y1 receptor knockout mice, or after co-administration of Y1 
antagonist. Similarly, Y1 receptor-mediated stimulation of neurogenesis and proliferation by 
NPY was also found in the mouse olfactory epitelium (Hansel et al., 2001). As mentioned 
above, NPY increased neurogenesis in the telencephalic subventricular zone (Decressac et 
al., 2010) but no receptor specificity was studied. In rat retinal cell cultures, NPY stimulated 
neural cell proliferation mainly via Y2 and Y5 receptors but some role of Y1R was also 
postulated as Y1 antagonist decreased the cell proliferation induced by NPY (Alvaro et al., 
2008). 
Neurogenesis, proliferation and differentiation of neurons may be also regulated by 
neurotrophic factors, and a cross-talk between NPY and brain derived neurotrophic factor 
(BDNF) in the mammalian brains has been suggested. Seizures and excitotoxicity induced a 
significant increase in BDNF in the injured region (Ballarin et al., 1991; Dugich-Djordjevic et 
al., 1992; Humpel et al., 1993). As the increase in BDNF always precedes the NPY expression 
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(Reibel et al., 2000) the BDNF overexpression after excitotoxicity may be neuroprotective by 
inducing NPY production. Many studies have shown that BDNF enhanced an expression of 
NPY in the striatum, cortex and the hippocampus (Barnea & Roberts, 2001; Barnea et al., 
2004; Nawa et al., 1994; Reibel et al., 2000; Takei et al., 1996; Wirth et al., 2005; Yoshimura et 
al., 2009). In the mouse organotypic hippocampal slice cultures exposed to glutamate 
receptor agonist, degeneration of CA1 and CA3 pyramidal neurons was diminished by Y2 
receptor agonist and such protection strongly inhibited the stimulating effect of AMPA on 
the BDNF level (Xapelli et al., 2008). It was also found that NPY treatment decreased BDNF 
and increased nerve growth factor production in the rat hypothalamus (Gelfo et al., 2011). 
All these results indicate mutual relations between NPY and BDNF (or maybe other trophic 
factors). 
Nitric oxide (NO) a reactive free radical, gas produced enzymatically from L-arginine by 
NO synthases is a very important molecule connected with the NPY role in excitotoxicity 
and neuroprotection. In normal physiological state, NO concentration in the brain amounts 
to less than 10 nM and NO plays an important role in vascular tone, blood pressure and 
neuronal signaling (Garthwaite, 1991) but during cerebral ischemia NO production 
increased which is an important factor inducing ischemic damage, as NO quickly forms 
highly toxic radicals (Matsui et al., 1999). It was found that in the rat MCAO model of 
ischemia, the brain NO concentration increased and intracerebroventricular injection of NPY 
or Y1R agonist enhanced this increase, while, in contrast, a Y1R antagonist strongly 
inhibited the NO formation. The results indicated harmful effect of Y1R stimulation via an 
increase in toxic NO formation. On the other hand a possibility of neuroprotection in 
ischemia by agents blocking Y1 receptors may be suggested. 
3. Conclusions 
Neuropeptide Y (NPY) reveals many important regulatory function in the brain both under 
physiological and pathological conditions. The present paper reviews the data on the role of 
NPY and its receptors in neuroprotection. The peptide counteracts neuronal glutamatergic 
excitation, inhibits seizures and has significant neuroprotective effects which are produced 
mainly via Y2 and Y5 receptors. The activation of Y1 receptors gives ambiguous results, 
usually induces harmful effects but in some situations and some brain regions may also be 
protective via both inhibition of glutamate release and the induction of repair mechanisms 
(cell proliferation, trophic factors or others). The results obtained by our group and by a few 
other authors suggest that NPY and Y2 or Y5 receptor agonists may reveal their protective 
activity not only when they are given before or simultaneously with a traumatic event but 
also as the delayed treatment, 30 min or even few hours after the onset of the damaging 
action. A possible role of NPY in some chronic neurodegenerative disorders is also 
discussed. 
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